Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

N/AApproved For MarketingNCT04300803

MorphoSys AG

Overview

Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen (tafasitamab@clinigengroup.com).

This program is intended to provide access to patients with relapsed and/or refractory DLBCL who had at least one prior anti-CD20 containing regimen. Patients with primary refractory disease and double/triple hit status are also eligible. Patients considering this access program should have no other therapeutic option, and are not eligible for other clinical trials. The expanded access program (MOR208N001) is currently available in the United States only.

Study Type

EXPANDED_ACCESS

Conditions

DLBCL

Interventions

Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progressionBIOLOGICAL

Expanded Access Program, Non-Interventional Study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Major Inclusion Criteria : 1. Age ≥ 18 years 2. Patient able to provide written informed consent 3. Histologically-confirmed diagnosis of DLBCL, including transformation from an earlier diagnosis of indolent lymphoma. 4. Patients must have relapsed and/or refractory DLBCL, including primary refractory disease and double/triple hit status, after at least 1 prior anti-CD20 containing regimen. 5. Patients with a serious, life-threatening illness in which conventional therapies have failed, are unsuitable and/or are unavailable and participation in ongoing relevant clinical trials is not feasible. Major Exclusion Criteria: 1. Patients who have other histological type of lymphoma, e.g. indolent Non-Hodgkin lymphoma (NHL), Primary mediastinal B-cell lymphoma (PMBL) or Burkitt Lymphoma 2. Patients who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period with lenalidomide 3. Patients with: 1. Known active bacterial and viral and fungal infections 2. Serology of chronic active viral Hepatitis B and/or C-Hepatitis 3. Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV) 4. Patients who are unable to participate in the lenalidomide REMS program

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.